NCT04263857 Register of Blood Stem Cell Transplantation
| NCT ID | NCT04263857 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Technical University of Munich |
| Condition | Hematologic Malignancies |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2017-11-01 |
| Primary Completion | 2037-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2017-11-01 with a primary completion date of 2037-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Register of patients with blood stem cell transplantations (autologous, allogen).
Eligibility Criteria
Inclusion Criteria: * signed IC * patients eligible for stem cell transplantation Exclusion Criteria: * unable to consent to study participation
Contact & Investigator
Mareike Verbeek, MD
PRINCIPAL INVESTIGATOR
Klinikum rechts der Isar der TU Munich, Germany
Frequently Asked Questions
Who can join the NCT04263857 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04263857 currently recruiting?
Yes, NCT04263857 is actively recruiting participants. Contact the research team at mareike.verbeek@tum.de for enrollment information.
Where is the NCT04263857 trial being conducted?
This trial is being conducted at Munich, Germany.
Who is sponsoring the NCT04263857 clinical trial?
NCT04263857 is sponsored by Technical University of Munich. The principal investigator is Mareike Verbeek, MD at Klinikum rechts der Isar der TU Munich, Germany. The trial plans to enroll 5,000 participants.